Skip Navigation
Skip to contents

JPMPH : Journal of Preventive Medicine and Public Health

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Ye Jee Kim 1 Article
The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia.
Joongyub Lee, Nam Kyoung Choi, Sun Young Jung, Ye Jee Kim, Jong Mi Seong, Seung June Oh, Byung Joo Park
J Prev Med Public Health. 2009;42(3):165-170.
DOI: https://doi.org/10.3961/jpmph.2009.42.3.165
  • 5,044 View
  • 61 Download
  • 6 Crossref
AbstractAbstract PDF
OBJECTIVES
We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH). METHODS: We used the Health Insurance Review and Assessment Service database from January 1st 2005 to June 30th 2006 for this study. The male patients with BPH and who had a prescription for alpha blockers following any fractures were defined as the cases. We set the 20 day long hazard period prior to the index date and the four control periods whose lengths were same with hazard period. After 1:4 matching of the hazard and control periods, conditional logistic regression was used to calculate the odds ratios for the risk of fractures as related to the alpha blocker exposure. RESULTS: Doxazosin and tamsulosin showed the increased risk of fractures, whereas terazosin did not. After stratification using the defined daily doses, a protective effect was shown for the patients who took terazosin at the doses lower than 0.4 DDD and the hazardous effect at the doses higher than or equal to 0.4 DDD. There was no significant difference for the risk of patients taking tamsulosin at the doses higher than 1.0 DDD but there was a statistically significant increase in the risk at the doses higher than or equal to 1.0 DDD. CONCLUSIONS: Alpha blockers for BPH may increase the risk of fracture in elderly patients who have comorbidities and take the concomitant medications. Alpha blockers need to be prescribed with caution, although some have high prostate specificity.
Summary

Citations

Citations to this article as recorded by  
  • Risk for Hip Fracture due to Alpha Blocker Treatment in Korean Women: National Health Insurance Database Study
    Gi H. SEO, Sung R. SHIM, Hwan W. LEE, Jin H. KIM, Dong‐Il CHUN, Hyun J. KIM, Hyun Y. LEE, Jae H. KIM
    LUTS: Lower Urinary Tract Symptoms.2018; 10(2): 175.     CrossRef
  • Risk of hip/femur fractures during the initiation period of α‐adrenoceptor blocker therapy among elderly males: a self‐controlled case series study
    Chao‐Lun Lai, Raymond Nien‐Chen Kuo, Ho‐Min Chen, Ming‐Fong Chen, Kinwei Arnold Chan, Mei‐Shu Lai
    British Journal of Clinical Pharmacology.2015; 80(5): 1208.     CrossRef
  • The Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures
    Sian Yik Lim, Pavis Laengvejkal, Ragesh Panikkath, Kenneth Nugent
    The American Journal of the Medical Sciences.2014; 347(6): 463.     CrossRef
  • Alpha-adrenergic blocker mediated osteoblastic stem cell differentiation
    Yoon Jung Choi, Jue Yeon Lee, Seung Jin Lee, Chong-Pyoung Chung, Yoon Jeong Park
    Biochemical and Biophysical Research Communications.2011; 416(3-4): 232.     CrossRef
  • Risk of fractures associated with treatment for benign prostate hyperplasia in men
    P. Vestergaard, L. Rejnmark, L. Mosekilde
    Osteoporosis International.2011; 22(2): 731.     CrossRef
  • Databases in Asia and Record-Linkage
    Kiyoshi KUBOTA
    Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku.2011; 16(1): 27.     CrossRef

JPMPH : Journal of Preventive Medicine and Public Health